Introduction and Objective: Epithelial to Mesenchymal transition (EMT) at the first hormonal therapy is thought to play an essential role in obtaining castrate resistance for hormone naïve prostate cancer. So we studied EMT of prostatic cells after exposing various hormonal agents using transurethral resection (TUR) specimens. Patients and Methods: TUR specimens without hormonal use (4 cases), specimens after three weeks of chlormadinone acetate (CMA) (9 cases), specimens after average six months of dutasteride (3 cases), and specimens two weeks after initial use of degarelix (3 cases) were studied using HE and immunohistochemical staining with prostate specific antigen (PSA), prostatic stem cell markers such as CD44, CD117, CD133 and Vimentin. Results: Specimens treated with CMA showed acinar dilatation and atrophy of glandular cells. Specimens treated with dutasteride showed marked decrease of gland and specimens treated with degarelix showed decrease of glandular cells. PSA was stained all of the prostatic glandular cells in all specimens. CD44 was stained at basal cells in normal prostatic tissue without hormones, however in hormone treated specimens, basal cells elongate and some glandular cells were also stained by CD44, especially in CMA treated specimens. Only small numbers of infiltrating cells in interstitial tissue positively stained with CD 117 and CD 133 in all specimens. Vimentin was stained in all mesenchymal interstitial cells. Conclusion: Elongation of basal cells and increased sensitivity to CD44 in glandular cells, especially treated with CMA, were thought to the result of EMT of prostatic glandular cells.
process that allows a polarized epithelial cell to undergo multiple biochemical changes that enable it to assume a mesenchymal cell phenotype, including enhanced migratory capacity, invasiveness, elevated resistance to apoptosis and increased production of extracellular matrix components [1] . The role of EMT is thought to a process of tissue repair by some pathological stress, inflammation and injury. The EMT is also believed to be a critical step in the progression of cancers from both the pre-invasive to invasive state, and from organ confined to metastatic disease [2] . At prostatic tissue, EMT is reported to play an important role in progression of benign hyperplastic change [3] [4], carcinogenesis, acquiring apoptotic tolerance [5] , neuroendocrine differentiation and chemotherapy resistance [6] . Among these roles, EMT at the first hormonal therapy is thought to play an essential role in obtaining castrate resistance for hormone naïve prostate cancer as well as benign prostatic tissues [7] . So we studied EMT of prostatic cells after exposure of various hormonal agents (degarelix/LHRH antagonist as androgen deprivation, chlormadinone acetate as short course hormone and dutasteride/5-alpha-reductase inhibitor as a long-period hormonal use) using transurethral resection (TUR) of prostate for benign prostatic hyperplasia specimens.
Materials and Methods
TUR specimens without hormonal use (4 cases), specimens two weeks after initial use of degarelix (3 cases), specimens after three weeks use of chlormadinone acetate (CMA) (9 cases) and specimens after average six months use of dutasteride (3 cases) were studied using Hematoxylin and Eosin (HE) and immunohistochemical staining with prostate specific antigen (PSA), reported prostatic stem cell markers [3] such as CD44 (Gene Tex Hsinchu, Taiwan), CD117 (c-kit) (abcam Cambridge, England), CD133 (ENOGENE NY, USA) and Vimentin (Santa cruz Dallas USA). One of the microscopic preparations from each surgical specimens were presented for immunohistochemical analysis. Results were compared with control (specimens without hormone). Non-specific staining by artefact presumably caused by TUR procedure was excluded. Usual immunohistochemical method was used for these studies [8] . The project was evaluated and approved by institutional internal review board and patients were explained and approved on the use of their TUR specimens. The use and using period of these drugs were appropriate for preoperative medication of TUR for benign prostatic hyperplasia (CMA and dutasteride), or neo-adjuvant hormonal therapy (degarelix) for prostate cancer and TUR for irradiation.
Results
Stained results are summarized on a Table 1 
Discussion
EMT is reported to play a pivotal role not only for prostate organ development in embryogenesis but also for benign hyperplastic change and malignant tumorigenesis [4] [9] . Androgen deprivation causes EMT for both normal and malignant prostatic gland [10] . EMT induced by castration changes prostatic luminal cells into cancer stem cells (CSCs), and helps these cells to obtain apoptosis resistance by castration [5] . reported that CD133 did not enrich for stem cell activity in vivo in adult mouse prostates [16] . That may be consistent with our results. Meanwhile CD44 is important as malignant stem cell marker [17] , and CD44 positive cell was reported to play a crucial role for acquiring metastatic potential in prostate cancer [18] .
The possibility of molecular targeting therapy, inhibiting the activation of CD44 using mi-RNA was also reported [19] .
Our results suggested that three weeks administration of CMA showed one of a model of stem cell transformation of human prostatic cells in vivo.
Elongation of basal cells and increased sensitivity to CD44 in glandular cells, especially treated with CMA, were thought to the result of EMT of prostatic glandular cells. Six months use of dutasteride might be long enough to alter the structure of prostatic tissue, and degarelix had strong apoptotic activity to prostate cells even in a short period.
